Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
NeoProgen
company
About
Developing a first in class regenerative therapy using exosomes derived from immortalized Neonatal Stem Cells to treat Cardiac Diseases.
- 1 - 10
Details
- Last Funding Type
- Seed
- Last Funding Money Raised
- $1.50M
- Industries
- Therapeutics
- Founded date
- Sep 28, 2018
- Number Of Employee
- 1 - 10
- Operating Status
- Active
NeoProgen is a therapeutics company that focuses on advancing neonatal cardiac progenitor cells. The company specializes in the fields of biotechnology and cardiac therapy.NeoProgen was founded in 2018 and headquartered in Maryland, United States.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$1.50M
NeoProgen has raised a total of
$1.50M
in funding over 2 rounds. Their latest funding was raised on
Oct 17, 2019 from a Seed round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 17, 2019 | Seed | $1.50M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
NeoProgen is funded by 2 investors.
TEDCO
and UM Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
TEDCO
|
— | Seed |
|
|
— | Seed |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
